Alison R. Mercer-Smith

Alison R. Mercer-Smith

Auto-generated profile, based on publicly available information

Alison R. Mercer-Smith

Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
WJWulin Jiang
Wulin Jiang
Yuchen YangYuchen Yang
Yuchen Yang
AMAlison R. Mercer-Smith
Alison R. Mercer-Smith
AVAlain Valdivia
Alain Valdivia
Juli BagóJuli Bagó
Juli Bagó
SHShawn D. Hingtgen
Shawn D. Hingtgen
Enhanced induced neural stem cell therapy shows superior efficacy in treating triple-negative breast cancer brain metastases.

1 December 2015 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
KPKelly J. Park
Kelly J. Park
CWConstance Wu
Constance Wu
AMAlison R. Mercer-Smith
Alison R. Mercer-Smith
RDRyan A. Dodson
Ryan A. Dodson
TMTyler L. Moersch
Tyler L. Moersch
ANAngelika Niemz
Angelika Niemz

1 January 2015
Verified
Book Chapter
Closed access
GHGabriella T. Heller
Gabriella T. Heller
AMAlison R. Mercer-Smith
Alison R. Mercer-Smith
MJMalkiat S Johal
Malkiat S Johal

25 August 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
AMAlison R. Mercer-Smith
Alison R. Mercer-Smith
WJWulin Jiang
Wulin Jiang
Juli BagóJuli Bagó
Juli Bagó
AVAlain Valdivia
Alain Valdivia
MTMorrent Thang
Morrent Thang
SHShawn D. Hingtgen
Shawn D. Hingtgen
Converting human fibroblasts into personalized induced neural stem cells (hiNSC) that actively seek out tumors and deliver cytotoxic agents is a promising approach for treating cancer. Herein, we provide the first evidence that intravenously-infused hiNSCs secreting cytotoxic agent home to and suppress the growth of non–small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Migration of hiNSCs to NSCLC and TNBC in vitro was investigated using time-lapse motion analysis, which showed directional movement of hiNSCs to both tumor cell lines. In vivo, migration of intravenous hiNSCs to orthotopic NSCLC or TNBC tumors was determined using bioluminescent imaging (BLI) and immunofluorescent post-mortem tissue analysis, which indicated that hiNSCs colocalized with tumors within 3 days of intravenous administration and persisted through 14 days. In vitro, efficacy of hiNSCs releasing cytotoxic TRAIL (hiNSC-TRAIL) was monitored using kinetic imaging of co-cultures, in which hiNSC-TRAIL therapy induced rapid killing of both NSCLC and TNBC. Efficacy was determined in vivo by infusing hiNSC-TRAIL or control cells intravenously into mice bearing orthotopic NSCLC or TNBC and tracking changes in tumor volume using BLI. Mice treated with intravenous hiNSC-TRAIL showed a 70% or 72% reduction in NSCLC or TNBC tumor volume compared with controls within 14 or 21 days, respectively. Safety was assessed by hematology, blood chemistry, and histology, and no significant changes in these safety parameters was observed through 28 days. These results indicate that intravenous hiNSCs-TRAIL seek out and kill NSCLC and TNBC tumors, suggesting a potential new strategy for treating aggressive peripheral cancers.

3 April 2023
Verified
Other
Open access
AMAlison R. Mercer-Smith
Alison R. Mercer-Smith
WJWulin Jiang
Wulin Jiang
Juli BagóJuli Bagó
Juli Bagó
AVAlain Valdivia
Alain Valdivia
MTMorrent Thang
Morrent Thang
SHShawn D. Hingtgen
Shawn D. Hingtgen
Converting human fibroblasts into personalized induced neural stem cells (hiNSC) that actively seek out tumors and deliver cytotoxic agents is a promising approach for treating cancer. Herein, we provide the first evidence that intravenously-infused hiNSCs secreting cytotoxic agent home to and suppress the growth of non–small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Migration of hiNSCs to NSCLC and TNBC in vitro was investigated using time-lapse motion analysis, which showed directional movement of hiNSCs to both tumor cell lines. In vivo, migration of intravenous hiNSCs to orthotopic NSCLC or TNBC tumors was determined using bioluminescent imaging (BLI) and immunofluorescent post-mortem tissue analysis, which indicated that hiNSCs colocalized with tumors within 3 days of intravenous administration and persisted through 14 days. In vitro, efficacy of hiNSCs releasing cytotoxic TRAIL (hiNSC-TRAIL) was monitored using kinetic imaging of co-cultures, in which hiNSC-TRAIL therapy induced rapid killing of both NSCLC and TNBC. Efficacy was determined in vivo by infusing hiNSC-TRAIL or control cells intravenously into mice bearing orthotopic NSCLC or TNBC and tracking changes in tumor volume using BLI. Mice treated with intravenous hiNSC-TRAIL showed a 70% or 72% reduction in NSCLC or TNBC tumor volume compared with controls within 14 or 21 days, respectively. Safety was assessed by hematology, blood chemistry, and histology, and no significant changes in these safety parameters was observed through 28 days. These results indicate that intravenous hiNSCs-TRAIL seek out and kill NSCLC and TNBC tumors, suggesting a potential new strategy for treating aggressive peripheral cancers.

3 April 2023
Verified
Other
Open access
AMAlison R. Mercer-Smith
Alison R. Mercer-Smith
WJWulin Jiang
Wulin Jiang
Juli BagóJuli Bagó
Juli Bagó
AVAlain Valdivia
Alain Valdivia
MTMorrent Thang
Morrent Thang
SHShawn D. Hingtgen
Shawn D. Hingtgen
Supplementary Data containing Figures S1-S9